Shandong Jincheng Pharmaceutical Group Co., Ltd (SHE:300233)
China flag China · Delayed Price · Currency is CNY
12.90
-0.49 (-3.66%)
Sep 10, 2026, 3:04 PM CST

SHE:300233 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
2,8002,7203,3533,5213,4843,127
Other Revenue
23.4616.8320.1817.6621.4611.78
2,8242,7373,3733,5383,5063,138
Revenue Growth
-5.08%-18.87%-4.66%0.93%11.70%5.96%
Cost of Revenue
1,8811,8122,0702,0731,9321,542
Gross Profit
942.65924.481,3041,4651,5741,597
Selling, General & Admin
544.24618.74842.741,035996.391,168
Research & Development
192.85188.46170.34184.71171.1178.34
Other Operating Expenses
41.2530.6827.8122.532.7930.74
Operating Expenses
782.84838.271,0381,2451,2001,373
Operating Income
159.8186.21265.27219.96373.34223.97
Interest Expense
-8.77-10.81-18.48-24.92-26.82-27.04
Interest & Investment Income
30.439.3712.915.1815.724.54
Currency Exchange Gain (Loss)
-8.73-0.537.581.340.97-10.1
Other Non Operating Income (Expenses)
1.552.75-2.2-3.32-2.52-4.49
EBT Excluding Unusual Items
174.2986.99265.08208.23360.66206.89
Gain (Loss) on Sale of Investments
-0.06-0.09-1.58-0.08-12.6-1.13
Gain (Loss) on Sale of Assets
50.983.23.37-1.981.531.18
Asset Writedown
-54.57-24.12-16.45-2.66-21.32-39.23
Other Unusual Items
20.9812.0318.0221.917.728.84
Pretax Income
191.6278.02268.45225.41345.97196.55
Income Tax Expense
52.8235.7560.7132.160.0973.47
Earnings From Continuing Operations
138.842.27207.74193.31285.88123.08
Minority Interest in Earnings
0.881.91-10.95-18.6-12.51-15.1
Net Income
139.6844.19196.78174.71273.37107.98
Net Income to Common
139.6844.19196.78174.71273.37107.98
Net Income Growth
27.47%-77.55%12.63%-36.09%153.15%-
Shares Outstanding (Basic)
359368378388385386
Shares Outstanding (Diluted)
359368378388385386
Shares Change
-6.49%-2.70%-2.53%0.84%-0.17%-0.60%
EPS (Basic)
0.390.120.520.450.710.28
EPS (Diluted)
0.390.120.520.450.710.28
EPS Growth
36.32%-76.92%15.56%-36.62%153.57%-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
302.19218.76153.97321.18-118.0461.04
Free Cash Flow Per Share
0.840.590.410.83-0.310.16
Dividend Per Share
0.1500.2500.2500.2000.1500.198
Dividend Growth
-40.00%0%25.00%33.33%-24.31%-1.82%
Gross Margin
33.38%33.78%38.65%41.40%44.89%50.87%
Operating Margin
5.66%3.15%7.86%6.22%10.65%7.14%
Profit Margin
4.95%1.61%5.83%4.94%7.80%3.44%
Free Cash Flow Margin
10.70%7.99%4.56%9.08%-3.37%1.94%
EBITDA
482.08405.21582.11525.43624.67443.16
EBITDA Margin
17.07%14.80%17.26%14.85%17.82%14.12%
D&A For EBITDA
322.27318.99316.84305.48251.33219.18
EBIT
159.8186.21265.27219.96373.34223.97
EBIT Margin
5.66%3.15%7.86%6.22%10.65%7.14%
Effective Tax Rate
27.56%45.82%22.62%14.24%17.37%37.38%
Revenue as Reported
2,8242,7373,3733,5383,5063,138
Advertising Expenses
---173.31198.82-